A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

NCT06256328 — Phase 2, Active not recruiting, 226 participants, Ono Pharmaceutical Co., Ltd.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

RegistryNCT06256328
StatusActive not recruiting
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: triple, treatment
Enrollment226 (Actual)
SponsorOno Pharmaceutical Co., Ltd. (Industry)
ConditionsGastric Cancer
InterventionsONO-4578, Oxaliplatin, Capecitabine, S-1, Nivolumab, Placebo (Drug)
Datesstart 2024-01-10, primary completion 2025-10-09, completion 2027-07-31 (estimated), first posted 2024-02-13, last updated 2026-03-13
Locations63 sites in Japan, South Korea, Taiwan

Related Papers Related Patents Related Grants Related Experts
All trials for Gastric Cancer All trials of ONO-4578 All trials of Oxaliplatin

-Summary

This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naïve participants with HER2- negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
ONO-4578+Nivolumab+chemotherapyExperimentalDrug: ONO-4578; Drug: Oxaliplatin; Drug: Capecitabine; Drug: S-1; Drug: Nivolumab
placebo+Nivolumab+chemotherapyPlacebo comparatorDrug: Oxaliplatin; Drug: Capecitabine; Drug: S-1; Drug: Nivolumab; Drug: Placebo
  • ONO-4578 (Drug): Specified dose, once daily
  • Oxaliplatin (Drug): Specified dose on specified days
  • Capecitabine (Drug): Specified dose on specified days
  • S-1 (Drug), also known as Tegafur-gimeracil-oteracil potassium: Specified dose on specified days
  • Nivolumab (Drug), also known as Opdivo: Specified dose on specified days
  • Placebo (Drug): Specified dose, once daily

+Outcome measures

Primary outcomes

  • Progression-free survival (PFS) (site investigator assessment) [up to 2years]

Secondary outcomes

  • Overall survival (OS) [up to 2years]
  • Objective response rate (ORR) (site investigator assessment) [up to 2years]
  • Best overall response (BOR) (site investigator assessment) [up to 2years]
  • Duration of response (DOR) (site investigator assessment) [up to 2years]
  • Disease control rate (DCR) (site investigator assessment) [up to 2years]
  • Time to response (TTR) (site investigator assessment) [up to 2years]
  • Maximum percent change in the sum diameters of the target lesions (site investigator assessment) [up to 2years]
  • Progression-free survival after the next line of therapy (PFS2) (site investigator assessment) [up to 2years]
  • Adverse event (AE) [Up to 30 days after the last dose]: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients with gastric or esophagogastric junction cancer histologically diagnosed as adenocarcinoma
* Patients have not been treated with systemic chemotherapy as first-line therapy
* Patients who can provide tumor tissue samples

Exclusion Criteria:

* Patients unable to take oral medicines
* Patients with HER2-positive
* Patients with contraindications to nivolumab, oxaliplatin, S-1, or capecitabine
* Patients who have a history of severe drug-related adverse reactions caused by non- steroidal anti-inflammatory drugs (NSAIDs) or who have complications caused by NSAIDs requiring treatment
* Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease, such as rheumatoid arthritis
* Patients with headache and/or nausea associated with brain metastasis

+Locations (63)

FacilityCityCountryStatus
Aichi Cancer Center HospitalNagoya, Aichi-kenJapan
National Cancer Center Hospital EastKashiwa-shi, ChibaJapan
Matsuyama Red Cross HospitalMatsuyama, EhimeJapan
NHO Shikoku Cancer CenterMatsuyama, EhimeJapan
Kyushu University HospitalFukuoka, FukuokaJapan
NHO Kyushu Cancer CenterFukuoka, FukuokaJapan
JCHO Kyushu HospitalYahatanishi-ku, Kitakyusyu-shi, FukuokaJapan
Gunma Prefectural Cancer CenterOta-shi, GunmaJapan
Hiroshima City Hiroshima Citizens HospitalHiroshima, HiroshimaJapan
Hyogo Cancer CenterAkashi-shi, HyōgoJapan
JOHAS Kansai Rosai HospitalAmagasaki-shi, HyōgoJapan
Kobe City Hospital Organization Kobe City Medical Center General HospitalKobe, HyōgoJapan
Ibaraki Prefectural Central HospitalKasama-shi, IbarakiJapan
Ishikawa Prefectural Central HospitalKanazawa, Ishikawa-kenJapan
Iwate Medical University HospitalYahaba-cho, Shiwa-gun, IwateJapan
Kagawa University HospitalMiki-cho, Kita-gun, Kagawa-kenJapan
Kitasato University HospitalSagamihara-shi, KanagawaJapan
Kanagawa Cancer CenterYokohama, KanagawaJapan
Osaki Citizen HospitalOsaki-shi, MiyagiJapan
Tohoku University HospitalSendai, MiyagiJapan
Kurashiki Central HospitalKurashiki-shi, Okayama-kenJapan
Osaka International Cancer InstituteChuo-ku, OsakaJapan
Kansai Medical University HospitalHirakata-shi, OsakaJapan
Osaka Metropolitan University HospitalOsaka, OsakaJapan
Kindai University HospitalSayama-shi, OsakaJapan
Osaka General Medical CenterSumiyoshi-ku, OsakaJapan
Osaka Medical and Pharmaceutical University HospitalTakatsuki-shi, OsakaJapan
Saitama Cancer CenterIna-machi, Kitaadati-gun, SaitamaJapan
Shizuoka Cancer CenterNagaizumi-cho, Sunto-gun, ShizuokaJapan
Cancer Institute Hospital of JFCRKoto-ku, TokyoJapan
IMSUT Hospital, The Institute of Medical Science, The University of TokyoMinato-Ku, TokyoJapan
Keio University HospitalShinjuku-ku, TokyoJapan
Kosin University Gospel HospitalBusan, Gangwon-doSouth Korea
Hallym University Sacred Heart HospitalAnyang-si, Gyeonggi-doSouth Korea
National Cancer CenterGoyang-si, Gyeonggi-doSouth Korea
CHA Bundang Medical Center, CHA UniversitySeongnam-si, Gyeonggi-doSouth Korea
Seoul National University Bundang HospitalSeongnam-si, Gyeonggi-doSouth Korea
Ajou University HospitalSuwon, Gyeonggi-doSouth Korea
The Catholic University of Korea, St. Vincent's HospitalSuwon, Gyeonggi-doSouth Korea
Pusan National University Yangsan HospitalYangsan, Gyeongsangnam-doSouth Korea
Jeonbuk national university hospitalJeonju, Jeollabuk-doSouth Korea
Chonnam National University Hwasun HospitalHwasun-gun, Jeollanam-doSouth Korea
Chungbuk National University HospitalCheongju-si, North ChungcheongSouth Korea
Dong-A University HospitalBusanSouth Korea
Keimyung University Dongsan HospitalDaeguSouth Korea
Kyungpook National University Chilgok HospitalDaeguSouth Korea
Yeungnam University HospitalDaeguSouth Korea
Gachon University Gil Medical CenterIncheonSouth Korea
Inha University HospitalIncheonSouth Korea
Asan Medical CenterSeoulSouth Korea
Kangbuk Samsung HospitalSeoulSouth Korea
Korea University Guro HospitalSeoulSouth Korea
Kyung Hee University HospitalSeoulSouth Korea
Samsung Medical CenterSeoulSouth Korea
Severance Hospital, Yonsei University Health SystemSeoulSouth Korea
The Catholic University of Korea, Eunpyeong St. Mary's HospitalSeoulSouth Korea
Ulsan University HospitalUlsanSouth Korea
Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung CityTaiwan
China Medical University HospitalTaichungTaiwan
Chi Mei Hospital, LiouyingTainanTaiwan
National Cheng Kung University HospitalTainanTaiwan
National Taiwan University HospitalTaipeiTaiwan
Chang Gung Memorial Hospital, LinkouTaoyuanTaiwan

+Publications

  • Results publication: Nakayama I, Ryu MH, Lim SH, Kim JG, Omori T, Oh SC, Kim JY, Rha SY, Lee KW, Machida N, Sym SJ, Narita Y, Park YI, Hara H, Hosaka H, Kang B, Kim IH, Bai LY, Hirashima Y, Hagihara S, Yamamoto T, Shitara K. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. J Clin Oncol. 2026 Aug 10;44(23):2198-2210. doi: 10.1200/JCO-26-01072. Epub 2026 Jun 1. PMID 42223130

+Investigators